Cargando…
Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis
Most multiple sclerosis (MS) patients given currently available disease-modifying drugs (DMDs) experience progressive disability. Accordingly, there is a need for new treatments that can limit the generation of new waves T cell autoreactivity that drive disease progression. Notably, immune cells exp...
Autores principales: | Tian, Jide, Song, Min, Kaufman, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940650/ https://www.ncbi.nlm.nih.gov/pubmed/33686135 http://dx.doi.org/10.1038/s41598-021-84751-3 |
Ejemplares similares
-
Homotaurine, a safe blood-brain barrier permeable GABA(A)-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis
por: Tian, Jide, et al.
Publicado: (2018) -
Transgenically Induced GAD Tolerance Curtails the Development of Early β-Cell Autoreactivities but Causes the Subsequent Development of Supernormal Autoreactivities to Other β-Cell Antigens
por: Tian, Jide, et al.
Publicado: (2009) -
Homotaurine Treatment Enhances CD4(+) and CD8(+) Regulatory T Cell Responses and Synergizes with Low-Dose Anti-CD3 to Enhance Diabetes Remission in Type 1 Diabetic Mice
por: Tian, Jide, et al.
Publicado: (2019) -
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
por: Liu, Rongzeng, et al.
Publicado: (2022) -
Increased risk for T cell autoreactivity to ß-cell antigens in the mice expressing the A(vy) obesity-associated gene
por: Yong, Jing, et al.
Publicado: (2019)